1. Home
  2. ACT vs BLCO Comparison

ACT vs BLCO Comparison

Compare ACT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enact Holdings Inc.

ACT

Enact Holdings Inc.

HOLD

Current Price

$40.64

Market Cap

5.7B

Sector

Finance

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$17.27

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACT
BLCO
Founded
1981
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Specialty Insurers
Ophthalmic Goods
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
6.0B
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
ACT
BLCO
Price
$40.64
$17.27
Analyst Decision
Hold
Hold
Analyst Count
3
14
Target Price
$40.67
$17.31
AVG Volume (30 Days)
252.2K
369.2K
Earning Date
02-03-2026
02-18-2026
Dividend Yield
2.06%
N/A
EPS Growth
1.64
N/A
EPS
4.36
N/A
Revenue
$1,224,897,000.00
$4,976,000,000.00
Revenue This Year
$4.60
$8.06
Revenue Next Year
$3.50
$5.79
P/E Ratio
$9.33
N/A
Revenue Growth
2.40
6.23
52 Week Low
$30.79
$10.45
52 Week High
$40.89
$18.34

Technical Indicators

Market Signals
Indicator
ACT
BLCO
Relative Strength Index (RSI) 62.85 58.68
Support Level $39.16 $16.22
Resistance Level $40.69 $17.55
Average True Range (ATR) 0.63 0.35
MACD -0.04 -0.02
Stochastic Oscillator 69.63 78.20

Price Performance

Historical Comparison
ACT
BLCO

About ACT Enact Holdings Inc.

Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: